Core Viewpoint - Tandem Diabetes Care, Inc. has announced the pricing of $265.0 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2032 in a private placement aimed at qualified institutional buyers under Rule 144A of the Securities Act [1] Group 1 - The offering of the convertible senior notes was upsized from a previously announced amount [1]

Tandem Diabetes Care, Inc. ( TNDM ) beat out expectations in Q4 '25. GAAP EPS came in at -$0.01, which was actually $0.05 above the consensus. Elsewhere, revenue for the quarter hit $290.4 million, up about 2.8% year-over-year and $13.16 million ahead of forecasts. There wereI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic rese ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Baird upgraded Henry Schein (HSIC) to Outperform from Neutral with a price target of $100, up from $78. The firm believes the bias across its dental names remains to the upside.UBS upgraded BlackRock (BLK) to Buy from Neutral with a $1,280 price target. The upgrade is supported by strong Q4 results, positive comme ...

Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded here. In the fourth quarter of 2025, the Small Company Fund (Investor shares) fell 1.50%, behind the Russell 2000® Growth index's 1.22% gain. Real estate and telecommunications businesses led the benchmark's performance for the quarter. The Fund was down 11.46% in 2025, significantly lagging the Index’s 13.0 ...

Core Viewpoint - Tandem Diabetes Care is transitioning to a more predictable and lucrative business model, resulting in significant profitability gains and a notable increase in stock price [1][3]. Group 1: Financial Performance - Tandem's sales increased by 3% year-over-year, reaching $290 million in the fourth quarter, with worldwide insulin pump shipments totaling 38,000 units, including 27,000 in the U.S. [3] - The company's gross margin improved to 58%, up from 56% in the same quarter last year, contributing to an operating income of $8.3 million, compared to a loss of $0.6 million in the prior-year period [5]. - The market capitalization of Tandem is currently $1.3 billion, with a stock price increase of 32.67% to $24.57 [4]. Group 2: Business Model and Future Outlook - Tandem is adopting a pay-as-you-go pharmacy structure, which reduces upfront costs for customers and generates recurring revenue, aligning with the company's goal of achieving more predictable and profitable revenue streams [3][7]. - For 2026, Tandem anticipates full-year sales between $1.065 billion and $1.085 billion, with projected gross margins of 56% to 57% [7]. - The CEO highlighted 2025 as a pivotal year, marking over $1 billion in worldwide sales and record gross margins while modernizing commercial operations and reshaping the business model [6].

The stock is moving higher as the broader market is experiencing positive momentum, with the Nasdaq up 0.62% today, contributing to the bullish sentiment.Earnings SnapshotTandem Diabetes on Thursday reported a smaller-than-expected fourth quarter adjusted loss of one cent compared to the consensus loss of eight cents.Sales increased 3% year over year to $290.4 million, beating the consensus of $277.03 million.Adjusted gross profit jumped from 51% to 58%. The company reported adjusted operating profit of $8. ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported better-than-expected fourth-quarter financial results on Thursday.Tandem Diabetes Care reported quarterly losses of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $290.400 million which beat the analyst consensus estimate of $277.029 million.Tandem Diabetes Care said it sees FY2026 sales of $1.065 billion to $1.085 billion, versus market estimates of $1.103 billion.“2025 was ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported better-than-expected fourth-quarter financial results on Thursday.Tandem Diabetes Care reported quarterly losses of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $290.400 million which beat the analyst consensus estimate of $277.029 million.Tandem Diabetes Care said it sees FY2026 sales of $1.065 billion to $1.085 billion, versus market estimates of $1.103 billion.“2025 was ...

Key Takeaways TNDM reported a Q4 loss of 1 cent per share as revenues rose 15.1% to $290.4 million, beating estimates. Tandem Diabetes achieved record U.S. and international pump shipments, lifting gross margin to 57.7%. TNDM guided 2026 GAAP sales of $1.065B-$1.085B after posting $1.01B in 2025 non-GAAP revenues.Tandem Diabetes Care, Inc. (TNDM) posted a fourth-quarter 2025 loss of 1 cent per share compared with a loss of 44 cents a year ago. The figure surpassed the Zacks Consensus Estimate of a loss of 5 ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Barclays upgraded Etsy (ETSY) to Overweight from Equal Weight with a price target of $72, up from $62. The firm sees the company's sale of Depop and its core business hovering around flattish after years of declines as a "tipping point" for Etsy, the firm tells investors in a research note. Argus upgraded Deck ...